

BrainCool AB (publ): Leading university hospital in the USA joins the Cottis 2 study

BrainCool, in consultation with the University Hospital in Freiburg, has concluded an agreement with the University of Maryland, Baltimore ("Maryland") to participate in the EU-funded Cottis 2 study, with Dr. Neeraj Badjatia as "principal investigator" for the hospital.

Maryland has participated in several clinical studies in thrombectomy and also another project with cooling and thrombectomy which has now been completed in order to have the opportunity to participate in BrainCool studies with the aim of establishing a new unique treatment for stroke patients, cooling treatment combined with thrombectomy.

CEO Martin Waleij comments;

"Through the participation of one of the leading trauma hospitals in the USA, the processes with both the FDA and the establishment of reimbursement on the market in the USA will be facilitated and accelerated. We already have a collaboration with Maryland in the field of neurological fever, which is financed by a research grant."

The financing of patient recruitment in the US within the Cottis 2 study will be covered with external funds.

Contacts

For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

Attachments

[BrainCool AB \(publ\): Leading university hospital in the USA joins the Cottis 2 study](#)